Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

PDF File

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 2, 2022-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the following investor conferences:

  • Guggenheim 2022 Oncology Virtual Conference on February 9, 2022 at 8:30 AM ET
  • 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 3:40 PM ET

A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of both webcasts will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

Investor Relations:
Maghan Meyers
Argot Partners
Deciphera@argotpartners.com
212-600-1902

Media:
David Rosen
Argot Partners
David.Rosen@argotpartners.com
212-600-1902

Source: Deciphera Pharmaceuticals, Inc.